S&P 500   3,968.25 (-0.23%)
DOW   32,467.56 (+0.11%)
QQQ   306.48 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
S&P 500   3,968.25 (-0.23%)
DOW   32,467.56 (+0.11%)
QQQ   306.48 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
S&P 500   3,968.25 (-0.23%)
DOW   32,467.56 (+0.11%)
QQQ   306.48 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
S&P 500   3,968.25 (-0.23%)
DOW   32,467.56 (+0.11%)
QQQ   306.48 (-0.74%)
AAPL   156.77 (-0.95%)
MSFT   273.51 (-1.04%)
META   200.29 (-1.26%)
GOOGL   100.90 (-1.52%)
AMZN   97.60 (-0.45%)
TSLA   188.57 (-1.69%)
NVDA   262.03 (-1.24%)
NIO   9.14 (+2.35%)
BABA   95.86 (+11.31%)
AMD   93.48 (-3.24%)
T   18.86 (-0.05%)
F   11.62 (+0.87%)
MU   58.40 (-2.32%)
CGC   1.87 (-0.53%)
GE   93.00 (-0.33%)
DIS   95.46 (-0.17%)
AMC   4.65 (+2.20%)
PFE   40.12 (-0.25%)
PYPL   72.53 (-1.05%)
NFLX   326.47 (-0.36%)
OTCMKTS:MRMD

MariMed - MRMD Stock Forecast, Price & News

$0.40
+0.02 (+5.30%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.38
▼
$0.40
50-Day Range
$0.38
▼
$0.48
52-Week Range
$0.28
▼
$0.77
Volume
236,222 shs
Average Volume
261,291 shs
Market Capitalization
$134.94 million
P/E Ratio
13.25
Dividend Yield
N/A
Price Target
$0.85

MariMed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
113.8% Upside
$0.85 Price Target
Short Interest
Healthy
0.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.22mentions of MariMed in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

See Top Rated MarketRank™ Stocks Here

MRMD stock logo

About MariMed (OTCMKTS:MRMD) Stock

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.

Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Stock News Headlines

March 25, 2023 | benzinga.com
MariMed Stock (OTC:MRMD), Dividends
March 6, 2023 | finance.yahoo.com
MariMed Inc. (PNK:MRMD) Q4 2022 Earnings Call Transcript
March 28, 2023 | Press Research (Ad)
Nevada Could be the Source for America's Green Future
Industry shift towards lithium driven by green energy goals
March 5, 2023 | finanznachrichten.de
MariMed Inc.: MariMed Reports Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023 | msn.com
Latest Executive Changes In Marijuana Industry, New Appointments & More
March 1, 2023 | finance.yahoo.com
MariMed Reports Fourth Quarter and Full Year 2022 Financial Results
March 1, 2023 | finance.yahoo.com
MariMed Board of Directors Appoints Edward Gildea as Chairman and Jon Levine as Chief Executive Officer
February 21, 2023 | finance.yahoo.com
MariMed To Expand Footprint in Massachusetts With Dispensary Acquisition in Quincy
March 28, 2023 | Press Research (Ad)
Nevada Could be the Source for America's Green Future
Industry shift towards lithium driven by green energy goals
February 1, 2023 | finance.yahoo.com
MariMed Announces Fourth Quarter 2022 Earnings Date
January 24, 2023 | finance.yahoo.com
MariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth Plans
January 17, 2023 | finance.yahoo.com
MariMed Strengthens Sales, Marketing, and R&D Teams With Senior Executive Hires
December 21, 2022 | finance.yahoo.com
MariMed Adds Candy Cane Flavored Vape Pen To Its InHouse Brand Line-up for the Holiday Season
December 14, 2022 | finance.yahoo.com
MariMed Appoints Jon Levine as Interim Chief Executive Officer
December 12, 2022 | finance.yahoo.com
MariMed Mourns the Passing of Robert Fireman, Chairman, CEO And Cannabis Industry Pioneer and Visionary
December 12, 2022 | finance.yahoo.com
MariMed searches for new CEO after death of Robert Fireman
November 21, 2022 | finance.yahoo.com
MariMed Announces Participation In Upcoming Conferences
November 21, 2022 | finance.yahoo.com
MariMed Announces Participation In Upcoming Conferences
November 16, 2022 | finance.yahoo.com
MariMed Supports Giving At Thanksgiving
November 8, 2022 | finance.yahoo.com
MariMed Reports Third Quarter 2022 Earnings
October 25, 2022 | benzinga.com
MariMed Enriches Betty's Eddies Line With Cannabis Chews To Empower Libido, Reduce Stress, Improve Sleep & More
October 25, 2022 | finance.yahoo.com
Answering The Demand for Cannabis Products That Meet Evolving Consumer Needs, MariMed Adds New Products To Its Top-Selling Betty’s Eddies Fruit Chews Line
October 18, 2022 | investorplace.com
3 Cannabis Stock Predictions for 2023 - InvestorPlace
October 13, 2022 | seekingalpha.com
MariMed Stock: Another MSO Overlooked (OTCMKTS:MRMD) - Seeking Alpha
October 12, 2022 | benzinga.com
MariMed Announces Third Quarter 2022 Earnings Date - MariMed (OTC:MRMD) - Benzinga
October 12, 2022 | finance.yahoo.com
MariMed Announces Third Quarter 2022 Earnings Date
October 5, 2022 | streetinsider.com
MariMed, Inc (MRMD) Opens its First Medical Cannabis Dispensary in Maryland - StreetInsider.com
See More Headlines
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Company Calendar

Last Earnings
11/15/2021
Today
3/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MRMD
CUSIP
N/A
CIK
1522767
Web
marimedadvisors.com
Phone
(617) 795-5140
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.85
High Stock Price Forecast
$0.85
Low Stock Price Forecast
$0.85
Forecasted Upside/Downside
+113.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.03
Trailing P/E Ratio
13.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$13.47 million
Net Margins
10.05%
Pretax Margin
14.56%
Return on Equity
27.89%
Return on Assets
9.80%

Debt

Debt-to-Equity Ratio
0.46
Current Ratio
1.67
Quick Ratio
0.93

Sales & Book Value

Annual Sales
$134.01 million
Price / Sales
1.01
Cash Flow
$0.06 per share
Price / Cash Flow
6.32
Book Value
$0.17 per share
Price / Book
2.34

Miscellaneous

Outstanding Shares
339,460,000
Free Float
260,232,000
Market Cap
$134.94 million
Optionable
Not Optionable
Beta
3.04

Key Executives

  • Jon R. Levine
    President, CEO, Secretary, Treasurer & Director
  • Timothy Shaw
    Chief Operating Officer
  • Susan M. Villare
    Chief Financial Officer
  • Jay O’Malley
    Vice President-Marketing & Research & Development
  • Ryan Crandall
    Chief Revenue Officer

Key Competitors

View All Competitors













MRMD Stock - Frequently Asked Questions

Should I buy or sell MariMed stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares.
View MRMD analyst ratings or view top-rated stocks.

What is MariMed's stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price targets for MariMed's stock. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they predict the company's share price to reach $0.85 in the next year. This suggests a possible upside of 113.8% from the stock's current price.
View analysts price targets for MRMD or view top-rated stocks among Wall Street analysts.

How have MRMD shares performed in 2023?

MariMed's stock was trading at $0.3562 at the start of the year. Since then, MRMD stock has increased by 11.6% and is now trading at $0.3975.
View the best growth stocks for 2023 here.

Are investors shorting MariMed?

MariMed saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 28,600 shares, an increase of 140.3% from the February 28th total of 11,900 shares. Based on an average daily volume of 428,300 shares, the short-interest ratio is presently 0.1 days.
View MariMed's Short Interest.

How were MariMed's earnings last quarter?

MariMed Inc. (OTCMKTS:MRMD) announced its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm earned $33.21 million during the quarter. MariMed had a net margin of 10.05% and a trailing twelve-month return on equity of 27.89%.

What guidance has MariMed issued on next quarter's earnings?

MariMed issued an update on its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150.00M-, compared to the consensus revenue estimate of $152.80 million.

What other stocks do shareholders of MariMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA).

What is MariMed's stock symbol?

MariMed trades on the OTCMKTS under the ticker symbol "MRMD."

How do I buy shares of MariMed?

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MariMed's stock price today?

One share of MRMD stock can currently be purchased for approximately $0.40.

How much money does MariMed make?

MariMed (OTCMKTS:MRMD) has a market capitalization of $134.94 million and generates $134.01 million in revenue each year. The company earns $13.47 million in net income (profit) each year or $0.03 on an earnings per share basis.

How many employees does MariMed have?

The company employs 260 workers across the globe.

How can I contact MariMed?

MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com.

This page (OTCMKTS:MRMD) was last updated on 3/28/2023 by MarketBeat.com Staff